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cooperation in the areas of health and social protection. 
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4         Executive Summary
KEY INSIGHTS
Industrial development in pharmaceuticals in Africa can support health system 
strengthening  
Developing local pharmaceutical production can improve access to medicines and help to 
generate the scientific, technological and skills base for building stronger and more resilient 
health systems. These health-industry mutual benefits also depend on funding and man-
aging competent, inclusive, population-focused health services, and on effective industrial 
regulation for quality assurance.
Local and global perspectives on emergency preparedness differ: both must be addressed
Global health security frameworks focus on technologies for emergencies that threaten the 
wider world. African experts shift the focus onto breaking supply constraints for recurrent 
lethal emergencies by building local supply capacities and organisational expertise. Both 
contributions are needed to build medium-term health security.
External actors can support an upward spiral of health-industry synergies
An upward spiral of industrial development and health system strengthening is emerging 
in some countries. External actors can support these synergies by linking up initiatives 
to strengthen access to medicines, through funding and procurement, to initiatives to 
strengthen the local industrial supplier base.
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CONTEXT
Low-income populations in sub-Saharan Africa (SSA) 
continue to suffer inadequate health care, undermined by 
poor access to medicines. In the context of Sustainable De-
velopment Goal (SDG) 3 and international commitments 
to universal health coverage (UHC), international inter-
vention finances large-scale international procurement 
of medicines and supports health system strengthening. 
Meanwhile, pharmaceutical manufacturing in SSA is long 
established, and is currently being promoted by African 
governments and other actors including the African Un-
ion Commission (AUC), the New Partnership for Africa’s 
Development (NEPAD) and the East African Community 
(EAC), and supported also by external actors including 
Germany’s Federal Ministry for Economic Cooperation 
and Development (BMZ). This Brief presents evidence for 
the actual and potential health and development benefits 
from creating stronger local and global linkages between 
these industrial and health agendas, and outlines how this 
can be done. 
THE SCOPE FOR LOCAL UPWARD SPIRALS: 
‘WIN-WINS’ FOR HEALTH AND INDUSTRIAL 
DEVELOPMENT
Industrial development in pharmaceuticals is currently 
observed to be interacting in a number of African coun-
tries with rising commitment to local funding of health 
supplies and to health system strengthening, in a virtuous 
upward spiral. Once underway, a mutual benefit lobby 
can emerge between local health system actors anxious 
to reduce supply shortages and arguing for higher pub-
lic funding, and local industrialists looking for larger 
markets. A ‘local health’ policy perspective identifies local 
health priorities and existing industrial capabilities, and 
then builds synergies and on-the-ground linkages be-
tween industrial and health system investments. In this 
way, local industrial development in pharmaceuticals can 
support health system strengthening through: 
•	 increased national government commitment to 
funding of medicines from domestic taxes, improving 
medicines access;
•	 improved pharmaceutical skills and training benefit-
ting health system management and procurement as 
well as industrial development;
•	 public and non-profit procurement becoming more 
responsive to local needs, by building linkages to 
close-to-market suppliers;
•	 improved rural access to medicines, as local firms 
respond to incentives to expand domestic distribution 
networks; 
•	 falling costs and prices as domestic industrial invest-
ment and market competition increase;
•	 shortened supply chains and hence faster response to 
emergency supply shortages; and
•	 reduced incidence of sub-standard medicines, as prox-
imity improves regulatory oversight and the share of 
public and non-profit procurement rises.
Many of these benefits are medium term: they require 
patience and commitment to build local health-industry 
linkages within markets and policy. This medium-term 
vision is also driving African commitments to building lo-
cal scientific and technological capabilities for production 
of vaccines and more complex treatments. 
HOW EXTERNAL ACTORS CAN SUPPORT 
THE MUTUAL HEALTH-INDUSTRY BENEFITS
 
External actors such as BMZ, who both work on health 
system strengthening and also support industrial devel-
opment, are well placed to link up these policy ‘silos’. Key 
areas where policies can have major mutual health-indus-
try benefits include: regulatory strengthening and harmo-
nisation; technological upgrading and improved quality 
assurance in local manufacturers; investment in skills and 
training in clinical and industrial aspects of pharmaceuti-
cals at all levels; and strengthening local procurement by 
international and local agencies through improved local 
health-industrial collaboration and market linkages. In 
working for mutual health and industrial improvement, 
an open-minded, project-based and problem-solving 
approach can extract early mutual benefits and generate 
moves towards policy coherence over time.
INDUSTRIAL DEVELOPMENT IS A SOCIAL 
DETERMINANT OF HEALTH 
 
Public health has enlarged its vision recently to include 
many intersectoral social determinants of population 
health. However, the impact of industrial development on 
health is still generally overlooked. Building more robust 
African health systems requires – and will effectively 
employ – the scientific and technological capabilities and 
skills generated by industrial development in pharmaceu-
ticals. As African governments develop their commitment 
to industrialisation, the global health community has 
much to contribute in supporting local health systems to 
extract the maximum benefits for public health.
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Opening reflection: two 
perspectives on health 
security 
The authors of this Brief on local pharmaceutical produc-
tion in Africa and its links to health system strengthening 
were asked to include evidence on the contribution of local 
production to pandemic and emergency preparedness. 
That request reflects the rapidly rising concern for health 
security and epidemic preparedness evident in the global 
health literature and within funding priorities. Contribu-
tions in the global literature, predominantly from indus-
trialised country authors in disciplines including security 
studies, development, foreign policy and international 
relations, tend to focus on protection of their citizens 
against ‘external [health] threats’ (Aldis 2008). At inter-
governmental level, the first-ever United Nations Security 
Council resolution on health was 13081, adopted in July 
2000, addressing the HIV/AIDS pandemic and its impact 
on peace and security (Rokvic and Jeftic 2015). There fol-
lowed other resolutions that covered the SARS outbreak in 
2003, the H1N1 pandemic in 2009, and the Ebola outbreak 
in 2014 (Rokvic and Jeftic 2015). In academic and policy 
discussions ‘health security’ has particularly addressed 
cross-border fast-moving infectious diseases, HIV and 
biological weapons/bioterrorism (Rushton 2011). A WHO 
Bulletin Editorial (Flahault et al 2016) recognises that ‘the 
concept of global health security underpins the cur-
rent framework for global preparedness and response to 
emerging infectious diseases’, aiming to strengthen global 
capabilities to detect, respond to and prevent their spread. 
Attention has focused on protecting the public health of 
high-income countries against infectious diseases ema-
nating from low- and middle-income countries. 
However, when we asked East African expert interviewees 
-- clinicians and pharmacists from the health sectors of 
Kenya and Tanzania -- about their priorities for emergency 
preparedness, their responses were sharply different from 
this global health perspective. With no exceptions, they 
prioritised current emergencies from which many people 
are dying now. In Tanzania, two pharmacists and a district 
medical officer identified as priorities dealing with recur-
rent shortages of emergency medicines such as saline drips, 
oral rehydration salts, oxytocin, hydrocortisone, magne-
sium sulphate and adrenaline. These shortages repeatedly 
cause deaths of children and adults in emergency situations. 
Both Tanzanian and Kenyan Ministry of Health respond-
ents also prioritised sustaining the supply of antiretrovirals 
(ARVs) for HIV and artemisinin combination medication 
(ACTs) for malaria as priorities to avoid potential large-scale 
emergencies. Furthermore, the African respondents, when 
asked specifically about pandemic preparedness, prioritised 
building local scientific capabilities to address pandemics, 
including local vaccine manufacturing capability, intellec-
tual property-linked partnerships with multinationals, and 
use of flexibilities under the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS). African 
respondents more broadly drew from experience an un-
derstanding that when nation states are faced with health 
emergencies, governments first protect their own nationals. 
The 2008-2009 flu pandemic was cited as a case where there 
was no plan to manufacture vaccines simultaneously for 
national and international requirements 2.
These different perspectives on emergency preparedness, 
which are not necessarily in contradiction, are explored 
further below. However, contrasts between arguments and 
frameworks of analysis of the health implications of the ge-
ographical location of productive and scientific capabilities, 
between the ‘international’ literature on the one hand and 
debates and policies within sub-Saharan Africa (SSA) on the 
other, run through this Brief as a whole. 
1   The resolution can be consulted at www.undocs.org/S/RES/1308(2000) 
2    Ethiopian expert commentator, 2011.
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INDUSTRIAL AND HEALTH CONTEXTS
In international research and policy debates, health system 
strengthening and industrial development have been and 
largely continue to be addressed within two separate silos 
(Mackintosh et al 2007, 2016a). In African government poli-
cy, and within pan-African institutions of research and pol-
icy, however, this has been changing. There is now strong 
recognition within African contexts that there are poten-
tially large developmental synergies to be extracted be-
tween expansion of industrial production of pharmaceuti-
cals and medical supplies and improvement of the coverage 
and quality of health care, especially for their low-income 
populations (African Union, 2007, 2012; EAC 2011; Berger 
et al 2010; Government of Kenya 2010; URT 2016; Govern-
ment of Uganda 2002; FDRE 2015; Gebre-Mariam et al 2016; 
Republic of Ghana 2004). International thinking has also 
shifted: the current World Health Organization (WHO) stra-
tegic framework for medicines and health products (WHO 
2017a: 8,12) recognises the relevance of local manufacturing 
of quality medicines and health products to support access, 
a view earlier emphasised by a joint declaration by the heads 
of the Joint United Nations Programme on HIV/AIDS (UN-
AIDS), the United Nations Industrial Development Organi-
zation (UNIDO) and WHO (Sidibé et al 2014), rooted in joint 
work by WHO, the United Nations Conference on Trade and 
Development (UNCTAD) and the International Centre for 
Trade and Sustainable Development (ICTSD) (WHO 2011a, 
UNCTAD 2011). By ‘local’ manufacturing, throughout this 
Brief, we mean manufacturing geographically located in 
low- and middle-income countries, and specifically in SSA, 
independent of ownership. 
Potential and actual synergies between local production of 
medicines and health commodities and access to medicines 
and treatment arise from market linkages. Health care 
constitutes a huge global market for industrial commodi-
ties: the global market for pharmaceuticals was estimated at 
USD 1072 billion in 2015 (Statistica 2017). Africa’s estimated 
USD 20.8 billion (2013) share is small but rapidly grow-
ing (McKinsey & Co 2015). Medical supplies, devices and 
equipment also constitute very large markets for industrial 
goods. African market size has been boosted by a huge 
inflow of philanthropic and governmental development 
aid for health since 2009. Of the estimated USD 36 billion 
development assistance for health in 2014 (the last year 
for which a breakdown of recipients is available), the share 
going to Africa was estimated at USD 14 billion, of which 
around USD 5.7 billion was earmarked for HIV (IHME 2017). 
The proportion of these funds going to purchase medicines 
and supplies is substantial but hard to establish. The Global 
Fund to Fight AIDS, Tuberculosis and Malaria (henceforth 
The Global Fund) estimates a spend of nearly USD 2 billion 
in 2016 on health products, mainly medicines and diagnos-
tics, through all its procurement channels, with a substan-
tial share for African countries 3. This is more than half of 
their USD 3.55 billion grant disbursements for 2016 (The 
Global Fund 2017). Health policies thus inevitably shape 
markets for industrial producers, for benefit or detriment 
(Reich 1990; Thomas 1994; Srinivas 2012).
From the health side, and despite this inflow of funds, 
low-income populations in SSA continue to suffer severely 
inadequate and exclusionary health care undermined by 
poor access to medicines and supplies (Wirtz et al 2017; 
Bigdeli et al 2014; Wagner et al 2011; WHO 2011b). Medi-
an availability of essential medicines 2007–2014 was only 
60% overall, and 56% in the public sector of low-income 
and lower-middle-income countries (WHO 2017b: 11). This 
availability has changed little over the period in African 
countries with time-series data (UN 2015: 55-6). While glob-
al health disparities have been reduced in absolute terms by 
concerted efforts to achieve the Millennium Development 
Goals (MDGs) and other health-related initiatives (WHO 
2013), major challenges remain in terms of reducing mater-
nal and child mortality, improving nutrition, and making 
further progress in the battle against communicable dis-
eases including HIV, tuberculosis (TB), malaria, neglected 
tropical diseases and hepatitis (WHO 2017b). 
3    Data provided by The Global Fund. 
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18 %
4  GIZ: http://eacgermany.org/wp-content/uploads/2017/02/GIZ-EAC-Factsheet-Socio-Economic-Integration-in-the-EAC-SCREEN.pdf ; PTB:     
   https://www.ptb.de/lac/index.php?id=eac ; UNIDO: 
   http://www.unido.org/pharmaceuticals.html ; UNCTAD: 
   http://unctad.org/en/Pages/DIAE/Intellectual%20Property/Building-local-pharmaceutical-production--supply-capacity.aspx 
5  www.health.bmz.de/what_we_do/hss/Healthy_Systems-Healthy_Lives/index.html 
The WHO African Region had the highest under-five mor-
tality rate (81.3 per 1000 live births) in 2015, almost double 
the global rate. The region also remains the worst affected 
by HIV, with SSA alone contributing 75% of the 1.8 million 
new infections globally in 2015 (GBD 2015 HIV Collabora-
tors, 2016). While there has been a 41% decline in recorded 
malaria cases between 2000 and 2015, Africa bears more 
than 90% of the remaining global burden of the disease: in 
2015, of the 429,000 malaria deaths recorded, 92% were in 
Africa, with children under five years accounting for more 
than 70% (WHO 2017b, 2016). Non-communicable diseases 
(NCDs) are also rising, as shown by the high prevalence of 
hypertension, a key tracer indicator of health services for 
cardiovascular diseases which has not declined in many 
low-income countries in Africa and Asia since 2000. The 
burden of NCDs in the WHO African Region is predicted to 
overtake the burden of mortality and morbidity from com-
municable diseases by the year 2030, due in part to lack of 
commitment to fund and implement measures to address 
the key risk factors for NCDs (WHO 2015).
International commitments to work towards universal 
health coverage (UHC) globally recognise the extent of the 
challenge in Africa (World Bank 2016), while the adoption 
of the Sustainable Development Goals (SDGs) has focused 
attention on improving inclusiveness of health systems. 
Unlike MDGs (2000-2015) which focused on programmes 
tailored to specific health conditions, SDG3 gives attention 
to performance of whole health systems including access 
to safe and affordable medicines and vaccines, and the pre-
vention of epidemics (WHO 2017a, 2017b). Better access to 
essential medicines and more appropriate use are required 
for all the aspects of health system strengthening listed in 
the UHC 2030 Joint Vision (WHO/World Bank 2017): for 
reducing severe inequity, and improving quality, respon-
siveness, efficiency and resilience.  
The context for this evidence brief is thus the convergence 
of continuing need in Africa for better access to essen-
tial medicines and supplies with expanding Africa-based 
industries producing pharmaceutical and health sector 
supplies. Pharmaceutical manufacturing in SSA is – contra-
ry to some external perceptions – long established and quite 
extensive (Banda et al 2016a), with long-standing industrial 
strengths in South Africa, Kenya and Nigeria in particular.
QUESTIONS 
This Evidence Brief addresses the linkages – positive and 
negative – between local industrial production of phar-
maceuticals in Africa and strengthening of African health 
systems. German development cooperation is supporting 
industrial development, including investment and upgrad-
ing of local pharmaceutical industries and the regulatory 
systems supporting them 4. It is also focusing on health sys-
tem strengthening in Africa, using an approach that aims 
to address interactions between health system components 
and also the impact of other sectors, such as education, on 
the performance of health systems 5. This Brief identifies 
ways in which industrial development can generate benefits 
for health, and vice versa.
We therefore do not ask one question familiar from the 
literature and debates – ‘Should Africa produce medicines?’ 
(Kardas-Nelson 2015) – since Africa has long done so and 
aims to produce more. We move away, furthermore, from 
another framing question in the international literature: 
‘Does local production of medicines in Africa benefit health 
care?’ Kaplan et al (2011) is a systematic review based on this 
approach. For our purpose here, this question is too broad 
to be usefully answerable: Any answer for policy purposes 
is, necessarily, ‘It depends’. This Evidence Brief therefore 
asks the more policy-relevant question, ‘What do beneficial 
health-industry linkages depend on?’ It asks specifically: 
•	 What are the factors that can and do sustain a positive 
health-industry spiral of mutual benefit? 
•	 To what extent have these factors been achieved? 
•	 Where and why have the linkages gone wrong? 
•	 What could be done to strengthen them? 
Methods and perspective: local health in a globalised world         9
6   See for example Mackintosh et al (2016b); Tibandebage et al (2014); Banda et al (2016b); Tait and Banda (2016); Mugwagwa (2015).
7   The Economic and Social Research Foundation, Dar es Salaam, Tanzania http://www.esrf.or.tz/ 
8   The methods and initial outputs of that project are available on the project website www.iphsp.acts-net.org . The project, Industrial Productivity  
    and Health Sector Performance, was funded by DFID and the UK Economic and Social Research Council (ESRC): the usual disclaimer applies (see  
    Acknowledgements).
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METHODS
This Brief is written by four authors: three of us collabo-
rated on a recent edited book, Making Medicines in Africa 
(Mackintosh et al 2016a), and have other recent research 
on pharmaceuticals and health systems in Africa6; the 
fourth is a researcher at a Tanzanian research and policy 
institution 7. Here we assemble and reflect upon the fol-
lowing sources of evidence: 
First, we updated and expanded the existing literature 
reviews for the Medicines book and other projects. As 
part of this process, we searched policy documents and 
‘grey literature’ on a wide range of topics related to local 
production of pharmaceuticals in low- and middle-in-
come countries, access to essential medicines and health 
sector supplies, and health system strengthening in SSA, 
and have assessed the quality of evidence. However this is 
not a systematic review: the criteria for inclusion in such 
reviews would retain too narrow a range of evidence for 
the questions addressed here.
Second, we have used and updated primary and second-
ary data and interviews from East Africa, with a par-
ticular focus on Kenya and Tanzania. The Brief draws on 
primary data collected by one of the authors and Kenyan 
and Tanzanian colleagues between 2012 and 2015 8. This 
primary evidence has been supplemented by 23 inter-
views undertaken in East Africa (Tanzania, Kenya, Ugan-
da) in April-May 2017. Many of these interviews involved 
multiple interviewees; they included six discussions with 
manufacturers, several of whom hold additional poli-
cy-related roles in manufacturing associations or philan-
thropic organisations; three with wholesalers (procure-
ment agencies or private distributors); three in regulatory 
bodies; two government ministry interviews; three with 
clinicians and pharmacists working in the health sector; 
two in university-level pharmaceutical education; two 
with consultants working in the pharmaceutical sector; 
and two with East African Community officials; we also 
met a group of senior informants at The Global Fund in 
Geneva. In addition, evidence is drawn from discussions 
by authors with a broader network of African experts, 
in the context of meetings and consultations on local 
production in Africa. All interviewees’ responses are 
unattributed, except where specific permission has been 
obtained. 
PERSPECTIVE: GLOBAL HEALTH AND LOCAL 
HEALTH
The global health field, with its focus on issues that 
‘transcend national boundaries and governments’ (Kick-
busch 2006), builds on earlier international health work 
that extended public health concerns across geographical 
boundaries (Battams and Matlin 2013; Macfarlane et al 
2008) to address tropical infectious diseases, access to safe 
water, combating malnutrition and promoting maternal 
and child health: a ‘synthesis of population-based preven-
tion with individual-level care; (Koplan et al 2009). Global 
health initiatives aim to address vast international dispar-
ities in mortality, morbidity and human wellbeing. Cam-
paigning and literature have focused around initiatives by 
‘global’ – that is, high-income country-based – actors to 
address these disparities. The major funding initiatives, by 
The Global Fund, the US President’s Emergency Plan for 
AIDS Relief (PEPFAR) and other multilateral and bilateral 
agencies have had hugely beneficial health effects, both 
in directly saving lives, and also, importantly, in refram-
ing understanding and obligation within high-income 
countries. 
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A concern with industry-health linkages does, however, 
identify key limitations of the ‘global health’ framing of 
analysis and policy. The focus on top-down, cross-border 
initiatives has diverted attention from developmental 
health-industry linkages within national, e.g. African, 
economies. Furthermore, the dominant public health per-
spective, while addressing some of the social determinants 
of health beyond the health system (Battam and Matlin 
2013; CSDH 2008), largely ignores the role played by indus-
try and by medical technological development in deter-
mining the operation of health systems. It also discounts 
the ways in which industrialisation and growth can 
underpin improving population health (López-Casasnovas 
et al 2005). The underlying global health assumption has 
been that medical health technologies are commodities 
readily available from global pharmaceutical value chains, 
and that affordability, timely availability and access are 
best addressed by global procurement, largely from Indian 
manufacturers. This perspective was reinforced by the 
dramatic successes in lowering prices for, especially, HIV 
medicines (MSF 2016; Waning et al 2010). 
This Brief summarises evidence relevant to high-income 
countries’ aid policies and, in that sense, is a contribution 
to the global health field. However, it examines its evi-
dence, on local manufacturing in Africa and its linkages 
to health systems, within a ‘local health’ perspective. 
That is, we are concerned centrally with local health-in-
dustrial synergies and their impact on developmental 
and health-related resilience within SSA. While recog-
nising that African health systems and manufacturers of 
medicines and other health products operate in strongly 
globalised markets, we summarise evidence on how these 
market, competitive and policy pressures are shifting, and 
the scope for the strengthening of local capability and 
agency. We focus on the scope for building competitive, 
high-quality local suppliers; the potential and actual bene-
fits for local health systems; and the impediments, failures 
and hurdles to be overcome. 
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Beneficial health-industry 
linkages: scope for an 
upward spiral  
OUR CONTENTION: LOCAL PRODUCTION 
OF MEDICINES CAN STRENGTHEN HEALTH 
SYSTEMS
Local health systems are culturally embedded social and 
economic institutions that must be built within national 
jurisdictions, and in Africa within the highly challenging 
context of liberalised trading conditions, cross-border in-
vestments, conditionalities on development aid for health, 
and highly constrained domestic health finance. There 
is no simple correlation – positive or negative – between 
national industrial development in pharmaceuticals in 
Africa and access to medicines and appropriate treatment. 
Nigeria, for example, has a large pharmaceutical indus-
try, but a very underfunded public health system and its 
population faces major financial constraints on access to 
treatment and a historically severe problem of counterfeit 
and substandard medicines (Wirtz et al 2017; Onwujekwe 
et al 2011; WHO 2011c). The Democratic Republic of Congo 
(DRC) lacks a large pharmaceutical industry and offers its 
population still worse access to reliable medicines, even in 
Kinshasa (ACT Watch Group et al 2017a). Outside Africa, 
India fails, despite its powerful pharmaceutical industry, 
to provide its people with reliable and equitable access to 
medicines (Srinivas 2016; Mackintosh et al 2016b). Con-
versely, Bangladesh, which has rapidly expanded its local 
pharmaceutical industry, has also achieved striking health 
care improvements (Ahmed et al 2013; Chowdhury et al 
2013). Whatever its industrial status, no country that lacks 
a government commitment to ensuring socialised funding 
and competent management of inclusive, population-fo-
cused health services can meet its population’s require-
ments for universal access to essential, good-quality 
medicines.
Our contention in this Evidence Brief is thus not that 
industrial production of pharmaceuticals is necessarily 
associated with good access to medicines. Rather, we argue 
that African and international evidence shows that local 
production of medicines can strengthen health systems. 
The determinants are national context and policy pro-
cesses, and external actors may support – or derail – both. 
The rest of this section draws mainly on evidence from 
East Africa, with some less detailed evidence from other 
regions of Africa.
LOCAL PHARMACEUTICAL PRODUCTION 
AND THE DOMESTIC MEDICINES MARKET IN 
EAST AFRICA: CONTEXTUAL BENCHMARKS
The context for analysing the health impact of local phar-
maceutical production in East Africa is, first, the scale and 
expansion of the industry to date, and second, its market 
structure and competition. The largest East African phar-
maceutical industry is in Kenya, made up of 39 firms (as of 
2014) located mainly in and around Nairobi (Simonetti et 
al 2016; UNIDO 2010a)9. Most firms produce basic essential 
formulations, tablets and capsules, syrups for children, 
and some creams. Two firms produce parenteral prepara-
tions, and one has been piloting production of the active 
anti-malarial ingredient artemisinin. One firm, Universal, 
has WHO-prequalification of a product line, allowing 
it to bid in international tenders funded, for example, 
by The Global Fund. Most firms in Kenya are East Afri-
can-owned. However Universal has just been taken over 
(51%) by Strides, a leading Indian pharmaceutical manu-
facturer, and Beta Pharmaceuticals is now owned (100%) 
by Aspen, a South African-based multinational. A variety 
of estimates, including unpublished primary survey data, 
and estimates from trade and production survey data (see 
Table 1) show that around one-third of Kenyan essential 
medicines consumption is of locally produced medicines. 
Kenya is also the only fairly substantial regional exporter 
of pharmaceutical products (see Figure 1 p. 15).
9  Details that follow are also drawn from interviewing in Kenya 2014-15, and 2017.
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Other East African countries have smaller pharmaceutical 
industries. Uganda in 2009 had 11 operating pharmaceuti-
cal firms (UNIDO 2010b), later expanded to 13 (EAC 2011). 
They include CIPLA Quality Chemicals, a joint venture 
which is now wholly integrated into the Indian multina-
tional CIPLA and which has WHO prequalification for 
some products; and also Kampala Pharmaceutical Indus-
tries, part of the Aga Khan network and the largest phar-
maceutical manufacturer in Uganda. The number of oper-
ating pharmaceutical firms in Tanzania fell from eight in 
2009 to five in 2014, with a resultant collapse in local firms’ 
market share (Tibandebage et al 2016) (see Table 1); it now 
(early 2017) stands at six, including a newly opened firm. 
Three firms in Tanzania are locally owned, of which two 
are small; one larger firm has recently been sold to Kenyan 
private equity capital, and the largest firm, Shelys, has been 
acquired by Aspen. Two other EAC members, Rwanda and 
Burundi, each have one pharmaceutical company.  
In the wider Eastern and Southern African region, Ethiopia 
is emerging as an expanding producer, with nine phar-
maceutical firms including Sino-Ethiop Associate (Africa), 
a joint venture producing and exporting hard gelatin 
capsules (Gebre-Mariam et al 2016). In Southern Africa, 
Brazilian capital was invested in a firm in Mozambique 
(Russo and de Oliveira 2016); Zimbabwe has sustained some 
pharmaceutical production through its economic crises 
(Banda et al 2016a); and the largest producer by far is South 
Africa, which also has some capability to produce active 
pharmaceutical ingredients (APIs) (Berger et al 2010). 
Local industry–health linkages in East Africa and their 
access implications are structured by the extent of the 
populations’ reliance on private purchase of medi-
cines. Stock-outs in public sector facilities and resultant 
reliance on out-of-pocket (OOP) purchase of medicines 
continue to exclude low-income populations across SSA 
from reliable access to treatment (Bigdeli et al 2014; WHO 
2011b; Ewen et al 2017). The problem is well documented 
in East Africa, even for the medicines supplied by inter-
national initiatives (Church et al 2017; Sudoi et al 2012; 
Talisuna et al 2012). Recent research confirmed wide-
spread and recurrent public sector stock-outs in both 
Kenya and Tanzania (Kariuki et al 2015; Tibandebage et al 
2014), with interviewees then, and for this Brief, confirm-
ing that patients are regularly sent to buy medicines from 
*Share calculated as (3) / ((1) + (3) – (2))
Sources: Author calculations from the following sources. 
Kenya: Imports, exports and local production: KNBS 2014, 2015. Mid-year exchange rates from Central Bank of Kenya (www.
centralbank.go.ke/ , consulted 17.2.16).
Tanzania: Imports and exports: Comtrade data base (www.comtrade.un.org/data/ , downloaded 5.8.14); local production URT 
(2012, 2013). Mid-year exchange rates from Bank of Tanzania (www.bot-tz.org/ , consulted 12.2.16).
TABLE 1. KENYA AND TANZANIA: PHARMACEUTICAL MARKETS 2009 AND 2013 (MILLION CURRENT US DOL-
LARS) AND MARKET SHARE OF LOCAL MANUFACTURERS (%)
COUNTRY AND 
YEAR
(1) IMPORTS 
(USD M)
(2) EXPORTS 
(USD M)
(3) LOCAL 
PRODUCTION 
(USD M)
LOCAL MARKET 
SHARE 
(%)* 
KENYA
2009 298.6 67.3 99.9 30
2013 466.4 82.1 193.1 33
TANZANIA
2009 99.4 7.9 49.2 35
2013 286.1 1.7 48.7 15
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shops. An official Kenyan estimate (MoMS & MPHS 2010) 
put the private share of total pharmaceutical expenditure 
at 80%; interviewees in Tanzania estimated that roughly 
half of medicines purchases were in the private sector. 
OOP expenditure on health was estimated at 26% (Kenya) 
and 23% (Tanzania) of total health expenditure and much 
of that spending will have been on medicines10. 
POTENTIAL ‘WIN-WINS’ FOR INDUSTRIAL 
DEVELOPMENT AND HEALTH SYSTEM 
STRENGTHENING
In this challenging context, the following are the areas of 
‘win-win’ initiatives that can benefit both industrial de-
velopment and health system performance. We provide 
evidence of the potentialities and of the impediments 
that can produce the opposite effect. 
Industrial development objectives can generate larger 
fiscal commitments for medicines access 
A combination of fiscal constraint, competing political 
priorities and reliance on donor funding for medicines 
procurement has sharply squeezed domestic tax-based 
funding for medicines in Tanzania and Kenya in recent 
years (Mackintosh and Tibandebage 2016). This squeeze 
has exacerbated public sector stock-outs of essential 
medicines that are not supplied by donor-funded pro-
grammes, including antibiotics and medicines for NCDs, 
pushing patients into the private market. Public sector 
prices are generally (though not always) lower than 
private sector prices for patients, and prices are zero 
for some patients in the public sector. A shift to better 
supply with fewer stock-outs is the best route to im-
proving medicines access in this health system context; 
the supply of ARVs and TB medication free of charge by 
donor-financed programmes reflects this recognition 
(Mackintosh and Mujinja 2010). 
It is interesting, therefore, that, in Tanzania in particu-
lar, a recent major shift in national policy focus towards 
industrial development has included a focus on rebuilding 
pharmaceutical production (URT 2016; 2015). Further-
more, this has been associated with sharply increased 
domestic funding commitments to purchase medication 
for the public sector. Thus the Tanzanian government has 
committed to greatly increase domestic funding for local 
procurement of essential medicines and health sector sup-
plies, announcing a planned annual allocation of Tshs 251 
billion (USD 112 million) for 2016-17 (BMI 2016a, 2017; and 
interviews), a huge increase on the previous year’s Tshs 80 
billion. The Treasury has also repaid much of its debt to 
the national procurement body (Medical Stores Depart-
ment, MSD), and the government has directly linked that 
funding commitment to objectives of local purchasing 
and industrial development, including increased domestic 
investment in MSD’s distribution infrastructure11. The 
Ministry of Health therefore, far from perceiving the na-
tional policy emphasis on industrialisation as competing 
with health care for tax funding, has embraced the scope 
for mutual benefit through increased local procurement. 
A mutual benefit lobby is emerging in Tanzania between 
health system actors anxious to reduce public supply 
shortages and arguing for higher public funding, and local 
industrialists looking for larger markets. 
Domestic procurement can improve responsiveness to 
local need
Can this collaboration work to benefit health? There are 
some reasons for positive expectations. First, from the 
industrial side, the limited data available suggest that 
public and non-profit procurement agencies already buy 
more locally than private wholesalers in the region. In 
Tanzania and Kenya, in 2013, a supply chain survey12  
found that for a sample of essential medicines (24 in 
Tanzania, 29 in Kenya), those sourced through private 
wholesalers were significantly less likely to have been 
bought from domestic manufacturers than those sourced 
by public wholesalers; the large faith-based wholesaler 
in Kenya (MEDS) was the most likely wholesaler in the 
survey to have bought locally. This was the case even 
though, at the time of the survey, very few medicines 
for HIV, malaria and TB, the main vertical programmes’ 
concerns, were sourced locally. Thus, more funding 
through these public and non-profit procurement bodies 
is likely to expand the market for domestic firms.
Second, from the health side, a case study of MEDS13, the 
Kenyan non-profit wholesaler, showed that it is possible to 
associate local procurement with a high level of respon-
siveness to local need. In interviews in 2013, faith-based 
Kenyan health facilities expressed considerable satis-
faction with MEDS’ response to supply gaps and specific 
requirements, and rapid turnaround on orders. MEDS in 
turn attributed its performance in good part to flexible 
contracting with local suppliers based on an approved 
supplier list monitored for qualihty and delivery times. 
The public procurement body in Tanzania, MSD, is now 
10   WHO NHA database (www.apps.who.int/nha/database/ViewData/Indicators/en , consulted 06.05.17)
11   Unreferenced statements in that sentence and the next summarise information from interviews with health sector key informants in Tanzania  
      in 2017. 
12   Source: Industrial Productivity project, see note 8.
13   Source: see note 13
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putting more effort into building comparable interactive 
links with individual local suppliers14. In Kenya, the health 
care decentralisation reforms have devolved public pro-
curement to the counties; the reforms aimed to improve 
responsiveness by the Kenyan public wholesaler, KEMSA 
(Kenya Medical Supplies Authority), to local needs. KEMSA 
is using framework contracts with local manufacturers to 
improve response times15. 
Health system interviewees in both countries in 2013 and 
2017 emphasised that shorter supply chains could and 
should enable more rapid and responsive supply to public 
health facilities. Interviewees also explained, however, that 
this outcome depended on much closer health-industry 
working relationships, including adaptation of contracting 
frameworks to address lead times, ordering, and payment 
schedules: in 2013, one non-profit wholesaler in Tanzania 
described difficulties it faced in buying from local suppliers 
that had resulted in longer lead times than ordering from 
India. MEDS’ experience shows that these problems can be 
overcome, but they require detailed attention to individ-
ual suppliers’ capabilities, well-designed contracting, and 
consistent communication with suppliers16. 
Third, in terms of mutual benefits for industry and health 
sectors longer term, there is documented evidence17 both 
of a resurgence of interest in pharmaceutical sector invest-
ment from local and international investors in the region, 
and also of some focus by new investors on gap-filling in 
response to identified and important national needs. The 
current active investment and proposals include creat-
ing more high-quality regional sources of combination 
antimalarial medication (ACTs) and of antiretroviral 
medication (ARVs) for HIV; also producing more key 
medication for NCDs including hypertension and diabetes; 
and increasing regional suppliers of intravenous drips and 
parenteral preparations. All of these items are currently 
largely imported. Simultaneously, local investors in Tanza-
nia have started to open production facilities for medical 
supplies such as bandages, in severe short supply, using 
locally produced inputs such as cotton. 
Local production can improve rural access to medicines
Availability of and access to basic medication is consist-
ently worse in rural as compared to urban areas, in both 
public and private sectors. Rural areas still contain much 
of the lowest-income population, and poor availability of 
medication arises from a combination of delivery difficul-
ties and also lack of demand (and hence profit) due to very 
low incomes (Cohen et al 2010; URT 2014; Mackintosh and 
Mujinja 2010). 
Small-scale surveys and qualitative evidence from Tan-
zania in 2008-9 showed that a high proportion of rurally 
available medicines had been made locally (Mackintosh 
and Mujinja 2010). Small sample survey data from 2013 
confirm that, even in Tanzania where local manufacturing 
output had been falling, a significantly higher proportion 
of essential medicines used as tracers and found on rural 
shelves (in facilities and shops) had come from local rather 
than imported sources (see Table 2).
In Kenya, the effect was even sharper (see Table 2) and in-
terviews also confirmed that local products were particu-
larly distributed and favoured in rural areas. In Tanzania, 
distribution of imported subsidised combination anti-
malarials was also found to be geographically patterned, 
with lower availability in remote areas (Cohen et al 2010). 
However, later evidence indicated that efforts to improve 
rural availability and use of these antimalarials, includ-
ing rural subsidies in Kenya, had largely closed the gap 
in Tanzania, Uganda, and Kenya (Morris et al 2015; ACT 
Watch Group et al 2017b).
14  Source : interviews 2017
15  Source: interviews 2017
16  Source: interviews 2013
17  Sources for this paragraph: interviewing 2017; data collection 2013.
TANZANIA   KENYA
LOCAL EXTERNAL LOCAL EXTERNAL
RURAL 19.8 80.2 54.9 45.1
URBAN* 13.0 87.0 35.5 64.5
TABLE 2. SOURCE OF TRACER ESSENTIAL MEDICINES AVAILABLE ON DAY OF VISIT, FACILITIES AND SHOPS, 
ALL SECTOR, BY RURAL/URBAN, TANZANIA AND KENYA, 2013 (% OF TOTAL BY RURAL/URBAN LOCATION).
Source: Calculated from fieldwork data 2013. Tanzania n=646; Kenya n=1043.
* In Tanzania, includes semi-urban areas on outskirts of cities and small urban areas in rural districts.
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Finally, analysis of WHO/Health Action International sur-
vey data in Tanzania on medicines availability and source 
showed that, in 2006 and 2009, the probability of finding 
a locally produced medicine (from a larger set of essential 
medicines) was not significantly different in rural and in 
urban areas, while imported medicines displayed ‘urban 
bias’, that is, they were much more likely to be found in ur-
ban facilities and shops (Mujinja et al 2014). Initial analysis 
of 2012 data18 confirms that this effect persisted in 2012, 
though with lower overall availabilities of local medicines 
because of the drop in local production noted above (see 
Table 1). Part of the explanation appears to lie in active 
distribution by local manufacturers, particularly, in 2006 
and 2009, by Shelys and Tanzania Pharmaceutical Indus-
tries (TPI) using their own distribution networks as well 
as local wholesalers. In Tanzania, an exit survey at private 
and non-governmental organisation (NGO) facilities and 
shops in 2008 picked up public satisfaction with these local 
brands (Mackintosh and Mujina 2010). A managing direc-
tor of another local manufacturer interviewed in 2017 rec-
ognised this distribution challenge: his firm was actively 
expanding both its in-house distribution capability and its 
brand recognition efforts. The implication of this evidence 
is that local firms, relying on the domestic market for 
the bulk of their sales, have an incentive to support and 
extend availability of basic medicines in more remote and 
rural areas, while importers are unlikely to address this 
challenge and may need subsidies to do so.
Health systems can benefit from close-to-market 
competitive suppliers when external buyers open market 
access opportunities for Africa-based firms
The very large rise in development aid for the purchase of 
medicines (see above) has greatly enlarged the medicines 
markets in East Africa. While trade data do not neces-
sarily capture all externally funded medicines, Figure 1 
shows the scale of net imports (the gap between the top 
line, imports and the lower, exports) in Tanzania, Uganda, 
Ethiopia and also, for comparison, Ghana in recent years. 
The expanding gap represents a source of serious health 
security concern for the medium term, since the imports 
require sustained hard currency funding and imply reli-
ance on Indian exporters who may not be committed to 
African markets in the longer term (Chaudhuri et al 2010); 
the gap also indicates the market opportunity for local 
manufacturers.
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FIGURE 1. PHARMACEUTICAL IMPORTS AND EXPORTS: AFRICAN COUNTRIES WITH RAPIDLY RISING IMPORT 
LEVELS AND FEW EXPORTS: TANZANIA, UGANDA, GHANA, ETHIOPIA: ANNUAL (USD MILLION)
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Source: Comtrade data (http://comtrade.un.org/data/ , downloaded 5.8.14).
18  Source: Ongoing work with Marc Wuyts and Mary Justin-Temu; initial finding used with permission.
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FIGURE 2. PHARMACEUTICAL IMPORTS 
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TRADE BALANCE: COUNTRIES WITH SUB-
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There is therefore widespread African concern about the 
scale of this import- and donor-dependence (see Figure 
1). Even countries with stronger industries and substan-
tial exports, such as South Africa and Kenya, have a large 
net import ‘gap’ (see Figure 2). Elsewhere, Bangladesh is 
a notable example of a country which has built up a local 
pharmaceutical industry and is achieving consistently 
rising exports and apparently stabilising import totals 
(see Figure 2).
The net imports in East Africa are largely externally 
funded, either through vertical programmes or via 
support for governmental and NGO medicines procure-
ment. Currently, this procurement is almost entirely from 
manufacturers in India, China or high-income countries, 
and the failure to ‘buy local’ has reduced market access 
for East Africa-based firms. The switch to combination 
antimalarial medication for first-line treatment in Tan-
zania, subsidised and supplied from India, caused large 
business losses to local producers of the previous first-line 
treatment, one firm losing an estimated one-third of its 
turnover19. The subsidy to public and private ACT prices 
has made the medication much more accessible for the 
population (ACT Watch Group et al 2017b), but has un-
dercut the viability of direct market supply by local firms: 
the market is dominated by a few major international 
purchasers for subsidised distribution. 
Until recently, it would be fair to say that most officers of 
large global funders – philanthropic funds, governments 
and large NGOs – have seen this issue as irrelevant to 
their concerns. As one interviewee from a large buyer put 
it20, he prefers ‘single sourcing, lowest price, economies 
of scale’. This has been a widely held view (Wilson et al 
2012), underlying commitments to pooled procurement at 
international level and to very large tenders with the aim 
of driving down procurement prices. There are under-
stood limits to the extent to which scale can drive down 
price (Waning et al 2010). Nevertheless, this approach 
to procurement is generally justified on the grounds of 
maximising the numbers treated with medication for 
HIV, malaria and tuberculosis21. Recently, however, the 
approach has been shifting. There is recognition, in the 
words of a philanthropic procurement manager, that 
there is no benefit in creating monopolies by driving 
prices down to the point where many suppliers leave the 
market. Nor is it possible to ignore the strongly expressed 
African concerns about the local industrial implications 
(see above).  
Source: Comtrade data (http://comtrade.un.org/data/ , 
downloaded 5.8.14).
19  Source: Interviewing for Mackintosh M and Mujinja PGM (2011) Interactions between Global Policy and Local Markets and Production of Medicines:  
     a case study in Tanzania Report to UNITAID, unpublished.
20  Source: interviews 2017
21  Source: Interviews 2017, see also Wilson et al (2012).
22  Information from The Global Fund cited with permission. 
U
SD
 M
ill
io
n
U
SD
 M
ill
io
n
U
SD
 M
ill
io
n
As a result, policies of large external buyers are being ad-
apted22. Both PEPFAR and the United Nations Internatio-
nal Children’s Emergency Fund (UNICEF) were said by in-
terviewees to take a flexible approach to buying from local 
manufacturers23. The Global Fund is also developing more 
local purchasing. The Global Fund’s guiding principles are 
value for money, quality (WHO-prequalification) and sus-
tainability, which means affordability: it will not subsidise 
firms. However, The Global Fund procurement system 
now works actively with potential African suppliers to 
assess their capabilities and potential. They recognise that 
the small number of Africa-based firms with products pre-
qualified by the WHO have found it difficult or impossible 
to win tenders against competition from large Asian sup-
pliers. Yet African manufacturers cannot improve, learn, 
invest and reduce costs unless they can sell, so where the 
externally funded market is dominant, the barriers to 
market entry have become very high. The Global Fund has 
also identified health system benefits from local supply, in 
particular proximity to market, resultant short lead times 
and responsiveness, and diversification of competitive 
sources of supply over time. 
For prequalified firms, The Global Fund therefore now 
uses a broader definition of value, called ‘total landed 
cost’, which includes points for shorter supply times than 
importers can achieve. Firms can develop their scores on 
the basis of advantages of proximity and include those 
in their tender. On this basis, The Global Fund is buying 
long-lasting insecticide-treated bed nets from A-Z, the 
large Arusha-based (Tanzania) manufacturer with good 
regional communications and logistics and much lower 
transport costs for a bulky product; it is also buying ACTs 
from CIPLA Quality Chemicals in Kampala. Furthermore, 
The Global Fund’s tenders are never ‘winner takes all’: 
the aim is to ensure a range of suppliers, not monopolies. 
Tender prices accepted will vary within one tender, so the 
tender outcome sets a ‘reference price’ for the particular 
item, and then a single price paid by each country from its 
allocation, which is never above the reference price. 
The implication of this procurement strategy towards 
local manufacturers is that there is scope for other funders 
to support complementary efforts at quality enhancement 
by Africa-based manufacturers to meet global standards 
‘as the Asian suppliers have done’24. The Global Fund ac-
cepts that this is a ‘journey’ for the Africa-based firms. The 
Global Fund will work with potential suppliers by making 
suggestions for reducing costs, e.g. by finding cheaper in-
puts, and collaborate with other funders by, e.g. providing 
market data. German and Japanese assistance in particular 
is playing a major complementary role in technology and 
quality upgrading. For the firms, Global Fund contracts 
are thus ‘the carrot at the end of the journey’.25 For the 
health system, by implication, the journey is towards an 
efficient, diverse and competitive supplier base for essen-
tial medicines and health commodities that is sustainable 
over time. 
Improved regulation of quality can benefit both industry 
and patients
It follows from the above discussion that quality assurance 
in manufacturers is a central win-win for both industrial 
suppliers and health systems, generating market access 
and safe medicines. The essential underpinning of quality 
assurance is provided by effective regulation. For the 
industrialists, good regulation provides, first, stimulus and 
pressure to attain safe recognised quality standards, and 
second, entry to markets for quality assured medicines. 
For health systems, effective regulation of local manufac-
turing ensures that locally sourced medicines and supplies 
– already widely used – are of reliable quality. 
Regulation, furthermore, is necessarily a shared enterpri-
se: it involves a complex mix of standard setting, inspec-
tion, enforcement, advice and support to meet standards, 
checking of procured supplies, post-market vigilance and 
following-up of complaints. Manufacturers and health 
system actors are in agreement that external support 
for regulatory improvement, at both national and East 
African regional level, has been central in reducing the 
incidence of sub-standard and counterfeit medicines in 
the private market, and in contributing to upgrading of 
quality across the local industry towards Good Manufac-
turing Practice (GMP) standards. External agencies inclu-
ding UNIDO, the Deutsche Gesellschaft für Internationale 
Zusammenarbeit (GIZ), PTB (Physikalisch-Technische 
Bundesanstalt – Germany’s national metrology institute), 
WHO, Drugs for Neglected Diseases (DNDi) and the World 
Bank have supported regulation and hence manufacturing 
improvement across the region.  
All manufacturers interviewed, in 2013 and 2017, in 
Tanzania and Kenya, were working on upgrading and 
improving their quality assurance systems. New investors 
coming in are now looking to start with internationally 
recognized GMP manufacturing standards26, and in order 
to assist local firms and investors, Kenya has developed the 
first of several regional roadmaps for upgrading local firms 
to achieve international GMP standards. Good regulati-
on supports joint venture development and technology 
transfer: one respondent from a multinational corporation 
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23  Interviews in Nairobi 2017 and in Dar es Salaam 2015.
24  Global Fund interviewee, 2017
25  Source: Interviews 2017: cited with permission
26   Source: Interviews 2017
with operations in Kenya stated that they were ‘aware of 
some of the key weaknesses of local pharma, for example 
around quality assurance and quality inspection proce-
dures, and would not want to put their reputation at risk’. 
The region, however, still lacks infrastructure such as 
sufficient high-quality reference laboratories for regulato-
ry work, and needs a stronger scientific and technical base 
to support these institutions. Regulatory effectiveness 
is uneven across the East African region, with Tanzania 
generally recognised as having the strongest regulator. 
External support for regulatory harmonisation initiatives 
across the East African region, to reduce the regulatory 
complexity of intra-regional exports, is widely appreciated 
by manufacturers and regulators, and NEPAD’s Africa Me-
dicines Regulatory Harmonisation (AMRH) is providing 
such a development platform. For local regulators, the 
regulation of local firms is in principle both simpler and 
more reliable than for external suppliers. Local firms can 
be visited regularly; Indian firms only once every three ye-
ars. However, there are complexities: regulatory ‘capture’, 
whereby regulation is weakened by political and financial 
influence, is an issue across the world. Supporting effecti-
ve independent regulators of local suppliers is one of the 
most useful roles for external actors, benefitting both the 
health and industrial sectors.
Sustaining domestic competition can lower costs and 
prices over time 
The most common accusation levelled at local manufac-
turers in African contexts is that they are not competitive: 
that their costs are too high, and scale and technological 
capability too low (Wilson et al 2012; Kaplan and Laing 
2005; Mohamed 2009; Rovira 2006; Seiter 2005), and that, 
as a result, a shift to local manufacture implies higher 
prices for patients. There is no doubt that African ma-
nufacturers suffer cost disadvantages, notably because 
of poor-quality but costly infrastructure such as power, 
water and transport. In basic formulations – making pills 
and tablets – economies of scale are not large, but African 
manufacturers have to import all their APIs in smaller 
quantities and at higher cost than competing Indian and 
Chinese exporters. However, the African manufacturers 
also have the advantage of proximity (their costs reduced 
by shorter supply lines) and knowledge of the domestic 
markets. Medicines prices fluctuate, and direct compari-
son of the prices of local and imported essential medicines 
is difficult and produces variable results. The local private 
markets tend to be quite competitive for basic items (Ma-
ckintosh and Mujinja 2010), and local manufacturers can 
meet competition by accepting lower margins than those 
earned on imports (Chaudhuri and West 2014).  
If local manufacturing is to flourish, some relatively small 
level of consistently applied trade protection is required 
while the industrial sectors develop. It takes a long time 
to develop local industrial capabilities and efficiencies 
to meet international competition, as the AUC’s 50-year 
development plan for Africa (Agenda 2063) recognises. 
‘Infant industry’ development is a well-recognised argu-
ment for protection, since it gives firms competitive brea-
thing space to improve capabilities (Sutton 2012; West and 
Banda 2016). The Indian government continues actively 
to support its pharmaceutical industry including export 
support. East African countries have therefore generally 
been offering for some years a price premium for public 
procurement: a percentage price uplift acceptable for a 
local tender as compared to imports. In Tanzania and 
Uganda this is 15%; in Kenya it varies from 10% down-
wards according to level of local ownership. However, 
in Kenya and Uganda interviewees said it had not been 
consistently applied in the past. In addition, other forms 
of protection are now under discussion, despite the zero 
common external tariff in the EAC. Uganda has applied 
a 2% verification fee on imports which may be raised to 
12%. Tanzania is discussing a list of products for local 
public procurement only, rather than external tender. 
Kenya has a draft Trade Facilitation Act that would allow 
complaints by local firms alleging dumping by external 
suppliers. Dumping of finished formulations below API 
cost is a genuine concern, with cases of apparent dumping 
documented by manufacturers .
The main constraint on price increases in the dome-
stic market is supplier competition, and it is essential to 
maintain domestic competition. What is sometimes called 
the ‘Ghana model’ of pharmaceutical industry promotion 
seeks to combine a market protected by blocking im-
ports of basic items that can be produced locally with the 
active promotion of a growing and competitive domestic 
industry. Ghana has had a short list of medicines for local 
supply only, and has very recently expanded that list to 49 
medicines, using a gazette Executive Instrument 181 (E.I. 
181), dated May 10, 201728. The banned medicines include 
antibiotics, analgesics, oral rehydration salts and multivit-
amins, and the Food and Drugs Authority (FDA) of Ghana 
will not accept new registrations of the medicines on the 
banned list. Ghanaian industry has received domestic 
support and external support (West and Banda 2016; BMI, 
2016b). The extent to which local production can deliver 
falling prices over time depends strongly on local context. 
In Bangladesh, domestic manufacturing has been associa-
ted with low prices but variable quality (Ahmed et al 2013). 
In Africa, ensuring market competition in the context of 
effective regulation will be the key to mutual industry-
health benefit.
27  Source for unreferenced statements in this paragraph: interviews 2014 and 2017
28  www.graphic.com.gh/news/general-news/no-more-import-of-49-medicines-local-manufacturers-to-fill-gap.html , accessed 10 June 2017.
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Investments in pharmaceutical training can benefit both 
health systems and industrial suppliers
Skills and training are the missing win-win: all sides em-
phasise and document the need for major improvement, 
but the commitments and therefore evidence of benefits 
remain thin. Interviewees agreed across the health-
industry divide that skills development and training were 
central to addressing their needs, and that the industrial 
and health needs overlap in pharmaceuticals. Health sys-
tem strengthening is widely agreed to need more effective 
pharmaceutical management, including supply chain ma-
nagement and procurement practices, but the systems lack 
the trained staff to achieve this (Wiedenmayer et al 2015; 
Yadav 2015; Waako et al 2009). In 2013, 53% of Kenyan and 
73% of Tanzanian health facility interviewees responsible 
for ordering had no training, short courses included29. The 
frontline health systems also need competent laboratory 
technicians. Nationally, medicines policy and manage-
ment for health needs excellent clinical pharmacists and 
pharmacological scientists. 
Many of these training needs overlap with the needs of in-
dustry, and industrial pressure allied to a commitment to 
industrial development can generate support for enhanced 
pharmaceutical training. Interviewees identified phar-
maceutical technicians as a large shared gap. Industrial 
laboratories also find it hard to recruit and retain skilled 
staff, who have to be trained on the job and are in short 
supply. Interviewees argued for a rethink of pharmacy 
teaching at tertiary level to include industrial skills and 
experience. The pharmaceutical industry particularly 
needs industrial pharmacy and chemical engineering 
training (Ministry of Health 2016), as well as biochemistry, 
microbiology, biomedical engineering and other allied 
sciences. Across the region, some tertiary institutions 
are introducing industry attachments, but much more is 
needed to generate the technical and scientific base for 
industrial growth. The need is particularly great in Tan-
zania, and is a real constraint on industrial development 
(MIT and UNIDO 2012). Pharmacy specialisms include in-
dustrial pharmacy, clinical pharmacy, drug designing and 
formulation; every level – pharmacy assistants (Certifica-
te), pharmacy technicians (Diploma) and degree level – is 
needed in both health and industry.
Medicines policy and regulation link health and indus-
try and also require major improvement in the pool of 
technically and scientifically trained people in all phar-
maceutical specialisms with an ability to work across the 
health-industry divide. As the head of one professional 
association put it, there is a need to ‘cook our own food’: 
professionalism and good regulation are central. Regu-
lation of a knowledge industry such as pharmaceuticals 
is underpinned by science, technology and innovation; 
medicines policy is underpinned by clinical skills; and the 
two need to work together locally. The Science Technolo-
gy and Innovation Strategy for Africa (STISA 2024) speaks 
to this realisation.  Regulatory and quality assurance 
laboratory skills are being built through initiatives such 
as U.S. Pharmacopeial Convention (USP) Ghana’s Center 
for Pharmaceutical Advancement and Training (CePAT) 
through a block release programme. In Southern Africa, 
collaborative efforts in regulation and skills training are 
being co-developed through the ZAZIBONA (Zambia, 
Zimbabwe, Botswana and Namibia) initiative, which mat-
ches experienced with inexperienced regulators in joint 
inspections across the four countries, to raise skills levels 
and feed into NEPAD’s AMRH programme. Industry and 
health benefit from faster turnaround, harmonisation of 
standards and better quality assurance. Skills inadequa-
cies do not only impede these ends, but, as one Kenyan 
respondent noted, they ‘also leave the few and over-stret-
ched professionals available vulnerable to manipulation 
through corrupt practices’ . Health and industry share a 
need for a stronger, better-skilled cadre of professionals, 
with clear career paths.
29  Source: Industrial Productivity project, see note 8.
30  Interviews in Nairobi 2017
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When a health system is challenged by emergencies or 
pandemics, its strength and resilience are demonstrated 
by its ability to ensure the health security of its citizens 
against the threat. The opening reflection identified some 
differing priorities between African health professionals 
and the ‘global’ health literature when emergencies and 
pandemics are addressed. No African health professional 
underestimates the dangers of haemorrhagic viruses such 
as Ebola. Rather, African professionals’ experience is of 
coping constantly with recurrent lethal emergencies in 
struggling, under-staffed and underfunded health sys-
tems. Policy makers and industrialists interviewed about 
medium-term threats to health security emphasised rising 
NCDs such as diabetes, hypertension and cancer: the Afri-
can Union’s Agenda 2063 emphasises the health implica-
tions of demographic shifts as young populations age.  
African and ‘global’ perspectives on emergencies and 
health security do not necessarily conflict. They do, how-
ever, generate distinct approaches to local health-industry 
linkages in African contexts, and to timelines in address-
ing local health security. Differences revolve around prior-
ities for immediate improvements in local health security, 
especially in strengthening ability to cope with emergen-
cies, and also around medium- to long-term priorities for 
sustainable and resilient strengthening of national health 
security in Africa in the face of both infectious and NCD 
burdens. Global health initiatives can benefit from much 
clearer specification of time perspectives: short-, medium- 
or long-term perspectives each require different tactical 
and strategic focus, especially when viewed through the 
combined lenses of socio-economic development, local 
health security, and generating local scientific-industri-
al-health linkages to build sustainable and resilient local 
health systems.
THE GLOBAL HEALTH FOCUS HAS 
LEVERAGED RESEARCH AND DEVELOPMENT 
TO CREATE A PIPELINE FOR NEW VACCINES 
AND TREATMENTS 
The concept of global health security underpins the 
current framework for global preparedness and response 
to emerging infectious diseases (Flahault et al 2016). The 
receptivity of the foreign policy and security communities 
to health aspects of security has a history that goes back to 
the Cold War and the shift in threats from nuclear to bio-
logical sources. The ‘security language’ increasingly used 
by global public health actors may, therefore, effectively 
have increased political attention and resources for global 
health issues (Elbe 2010; 2011; Rushton 2011; Rokvic and 
Jeftic 2015). The Global Health Security Agenda focuses 
on ‘strengthening capacities for detection, response and 
prevention’ (Flahault et al 2016). In this field the global 
health focus, for both high income countries and African 
societies, has been research efforts that have leveraged 
product development partnerships to produce a pipeline 
for new vaccines and treatments.
This effort, which has been an investment in solidarity as 
well as security, has the potential to save large numbers 
of lives. Product Development Partnerships (PDPs) such 
as the Malaria Vaccine Initiative (MVI), International 
AIDS Vaccine initiative (IAVI) and Medicines for Malaria 
Venture (MMV) have been generally well funded, and have 
enriched the product development pipeline for therapies 
that address health challenges for Africa. By garnering a 
critical mass of resources for research and development, 
PDPs have sharply reduced the risk involved in translating 
new medical technologies into treatments, by bridging the 
so-called ‘valley of death’ between research and applica-
tion. As a result, they have greatly increased the chances 
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for emergence of new therapies and promising treatments 
which would otherwise not have been possible without 
this type of innovative organisational setup. A number 
of the interventions, although not yet in the clinic, are in 
clinical trials. This has had the effect of improving clinical 
trial design and local trials management skills and capac-
ity. Broadening or localising the therapy development in-
novation pathways and technological capability building 
would call for inclusion of African vaccine organisations 
in the research and development activities by the PDPs 
where possible.
African policy actors acknowledge the scale and impor-
tance of global health efforts, just as many global health 
commentators are aware of limitations that include a 
perceived privileging of containment over prevention of 
infectious disease (Aldis 2008; Rushton 2011; Flahault et 
al 2016). The dangers of haemorrhagic viruses are active-
ly addressed by East African public health professionals. 
Tanzania, for example, implemented active port and border 
surveillance during the Ebola outbreak, picking up some 
suspected (negative) cases (WHO 2017c). To address techno-
logical capability building, initiatives such as the African 
Vaccine Manufacturing Initiative (AMVI) and the African 
Network for Drugs and Diagnostics Innovation (ANDI) aim 
to enhance local development activities by working with 
industry and research institutions respectively. 
AFRICAN HEALTH ACTORS PRIORITISE 
IMMEDIATE EMERGENCIES AND HEALTH 
SYSTEM RESILIENCE
African interviewees for this Brief consistently reacted 
questions about response to emergencies in two ways: first, 
by enumerating other recurrent, life-threatening emer-
gencies that their health systems were still struggling to 
deal with, and second, by emphasising the importance of 
broad health system capabilities and resilience in being 
ready to address pandemics and crises.  
Tanzanian and Kenyan lists of emergency priorities were 
very similar, particularly identifying emergencies of 
haemorrhage and dehydration. Failures to stop bleeding 
in childbirth, for example, because of a lack of anti-haem-
orrhage drugs, is responsible for many deaths, and lack 
of immediately available intravenous (IV) fluids prevents 
rehydration, particularly of young children. These gaps 
in the supply chain of essential inputs are further thrown 
into relief by cholera epidemics, such as that in Tanza-
nia in 2015. These inputs are all imported in Tanzania, 
though there are Kenyan and Ugandan IV manufacturers. 
Local firms find it hard to match external prices for IV flu-
ids; however health security concerns are driving efforts 
to develop and ensure a market for local production of 
IV fluids to ensure shorter supply lines and faster gap 
filling of these emergency supplies. These efforts include 
active technical support and monitoring for 60 hospitals 
to make their own IV fluids by a team at St Luke’s School 
of Pharmacy in Tanzania31  which has been supported by 
German technical cooperation. Kenyan interviewees also 
said that Universal had been able rapidly to supply low-
cost and effective oral rehydration salts to some African 
countries in the last few years to tackle outbreaks of 
diarrhoeal diseases.
Further causes of deaths in emergencies are lack of 
antibiotics such as penicillin. Tanzania has been losing 
local antibiotic production capability (Tibandebage et al 
2016a) and does not produce injectables, though there 
are Kenya-based firms with this capability. The public 
procurement agency in Tanzania is trying to diversify its 
suppliers of basic antibiotics, and to ensure availability 
of local suppliers in a crisis. Lack of anaesthetic drugs for 
surgery, adrenaline for allergy cases and medication for 
asthma are all important causes of emergency deaths. 
There was unanimity among the Tanzanian health sector 
interviewees that local manufacture of these items would 
potentially improve local health security by adding new 
close-to-user suppliers. 
Asked how emergency preparedness could be improved, 
Tanzanian interviewees emphasised the need to tackle un-
available supplies within the country. Kenyan interview-
ees, however, in a country with a much larger industrial 
base, particularly emphasised health sector organisation, 
logistics and distribution capability as key aspects of ef-
fectively accessing emergency supplies and making them 
available in a timely manner. They also picked up issues 
of laboratory capability, quarantine preparations, border 
control, records management and decision making. These 
responses echo an emerging view in the global health 
literature that pandemic preparedness centrally includes 
the strength and resilience of local health systems. Kenyan 
interviewees also saw lack of capability to tackle neglect-
ed tropical diseases as a further emergency issue. They 
noted that Kenya had the manufacturing capability it 
could build on: now it needed to improve the ability of the 
health system to use those capabilities in crises.  
LOCAL MANUFACTURING BRINGS 
TECHNOLOGY AND EXPERTISE TO SUPPORT 
AFRICA’S MEDIUM-TERM HEALTH SECURITY
Does geography, i.e. the location of expertise and manu-
facturing capability in pharmaceuticals, matter for health 
security? African interviewees all argued that it does: that 
national governments are responsible for national health 
security and that, in this regard, national technological 
31  Source: interviews 2017
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and scientific expertise is essential. African governments 
and inter-governmental bodies such as the EAC, AUC and 
NEPAD are all looking for ways to enhance local skills and 
capabilities, and many policy makers perceive manu-
facturing as a focal point for building improved security 
medium term.  
While most SSA pharmaceutical manufacturing consists 
of basic formulations using imported APIs, there are signs 
of a rising technological level, bringing with it the re-
quired scientific and technical capabilities. Scientists and 
manufacturers are looking for niches where API manufac-
turing can get started. Economies of scale are much more 
important in making APIs than in formulations, so it is 
hard for a smaller-scale producer to compete; it follows 
that potential market niches include low-dose APIs where 
the main market is in Africa, such as Entecavir for Hepati-
tis B (Fortunak et al 2016). Fine Chemicals in South Africa, 
which has benefitted from government support, produc-
es a number of APIs, and in Ghana La Gray has a small 
capacity for manufacturing an antibiotic (azithromycin) 
(Fortunak et al 2016). 
More broadly, joint ventures, technology transfer and 
external technical and funding support are shifting the 
manufacturing base towards more complex products and 
processes. The joint venture that created CIPLA Quality 
Chemicals brought technology, technical and manage-
ment skills and products to the Uganda plant. The buyout 
by Strides of a majority holding in Universal in Kenya has 
brought new products to the Kenyan plant32. In Ethiopia, 
the Sino-Ethiopian joint venture exporting hard capsule 
shells across Eastern and Southern Africa has transferred 
skills and technology effectively to the Ethiopian partner 
and staff33. New investor proposals in Tanzania aim to ad-
dress the gap in local supply of formulations for NCDs and 
ACTs, and expanding the regional base of ARV production. 
DNDi has supported upgrading of one firm to produce 
high-quality combination antimalarial tablets34. In Tan-
zania a Cuban-Tanzanian government joint biotechnology 
venture began in 2015 to use Cuban technology to produce 
biolavicides to control mosquitos; trials are currently un-
derway. In an unprecedented move, Biovac has transferred 
technology to Indonesia and Japan for a locally developed 
human papillomavirus (HPV) vaccine, showing scope 
for technological capability export from the continent. 
Recently, Biovac signed an agreement with Sanofi for the 
production of the Strep B Group vaccine. Effective transfer 
of technology and innovative expertise to local staff, to 
generate technological learning, is key to the impact of 
these investments for the health system, ensuring both 
their sustainability and a build-up of key skills within the 
country. 
These innovation and skills-building processes are impor-
tant for emergency preparedness. As a Kenyan inter-
viewee pointed out, the issuing of compulsory licences 
to manufacture depends on local production capabilities 
– and in a crisis there is also legal scope to supply other 
neighbouring countries without the relevant capacities. 
The use of TRIPS flexibilities is also open to manufactur-
ers in the region, including Kenya (Ogendi 2013), but a 
Kenyan interviewee argued that their use is being blocked 
by a fear of litigation by originator companies, and by 
companies’ lack of full awareness of Kenyan legislation to 
permit compulsory licencing. 
LOCAL VACCINE PRODUCTION IS 
CHALLENGING, BUT HAS PAYOFFS FOR 
HEALTH SECURITY
The incentive to build up national and SSA regional 
capabilities is particularly strong in pandemic medi-
cation and vaccines, where national security is threat-
ened, given the widely held assumption that in a global 
pandemic, high-income countries will treat and protect 
their own populations first. Vaccines and immunisation 
programmes are key components of saving lives and 
strengthening health systems. However, virtually all 
vaccines used in Africa are imported (USD 1.2 billion in 
2013), since the five key manufacturers produce only 1% 
of requirements. According to the Vaccine Manufactur-
ing and Procurement in Africa Study (AVMI/UNIDO/
WHO, no date), in Africa 37 countries procure all vaccines 
through UNICEF, and Africa’s share of UNICEF’s total pro-
curement is around 60%. Senegal’s Institut Pasteur Dakar 
produces a WHO-prequalified yellow fever vaccine, while 
South Africa’s Biovac (a local public/private partnership) is 
engaged in late-stage vaccine development while currently 
producing vaccine vials using imported APIs. 
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Vaccine manufacturing development is particularly 
challenging because of high levels of global competition 
from large producers, and high levels of pooled pur-
chasing by UNICEF with development aid funding. The 
largest funder is the GAVI Alliance35, which generally 
requires UNICEF procurement for its funded vaccines 
(ibidem). However, the AVMI study put health security at 
the top of the list of reasons for exploring the scope for 
a shift in manufacturing capability to Africa, followed 
by addressing specific and unmet needs and pandemic 
preparedness (ibidem).  
Vaccines are risky products with high barriers to mar-
ket entry and long lead times for product development. 
However the same study argues that there is potential for 
local production in the next 10 to 20 years, given project-
ed population growth. It suggests that regional hubs are 
likely to be the best strategy, but they require political 
and technical support, an area of advocacy and technolo-
gy addressed by AVMI.
Vaccine and biological production is thus at the high 
end of the challenges for local production. Investment 
of USD 60-100 million is required to set up a manufac-
turing facility (ibidem), but the payoffs in terms of both 
skill level and medium-term national health security are 
also high. Moves towards expansion of vaccine manu-
facturing would build on developing biological product 
manufacturing and also clinical trials experience which 
is extensive in South Africa. Initiatives would require 
technology transfer, e.g. through joint ventures; current 
experience also suggests the need for government and 
philanthropic support. Regulatory capability would need 
to be built up, and local procurement and funding devel-
oped. The African Vaccine Regulatory Forum (AVAREF) 
is active in this area. 
Emergencies, pandemics and medium-term health security: global and local priorities
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Policy implications: how 
external actors can sup-
port local health-industry 
synergies
LINKING THE POLICY SILOS
Many external agencies already work on both sides of the 
health-industry divide, and some are now trying to link 
up the policy silos. The WHO has deep involvement in 
industrial technology and regulation in pharmaceuticals 
as well as leading international work on UHC. German 
development cooperation has a strong track record in both 
health system strengthening and industrial development 
in Africa. From the evidence presented, the following 
stand out as areas where external actors can usefully 
extract synergy from linking their activities, or can reach 
out to other actors across the policy divide to support an 
upward spiral of mutually beneficial local health-industri-
al linkages in Africa. 
SUPPORTING INCREASED MEDICINES 
ACCESS THROUGH PUBLIC AND NON-
PROFIT SUBSIDISED ROUTES
Development funding for quality assured medicines has 
made a crucial contribution to saving lives. Across East 
Africa these medicines are generally made available free 
of charge to ensure maximum access, the main excep-
tion being subsidised ACTs for private distribution. More 
broadly, in African contexts medicines procured through 
non-governmental non-profit and public procurement are 
consistently of better quality than private market medi-
cines, and are also more affordable. Finally, stock outs and 
leakages to the private sector from public systems are one 
of the major constraints on access to medicines. 
It follows that external support for a wide variety of ‘so-
cialised’ routes to medicines access is likely to improve the 
inclusiveness of health systems with respect to medicines 
access and the objective of UHC. A shift in access routes 
away from private markets purchase is also beneficial 
since these markets still contain a higher share of sub-
standard and counterfeit items than the public sector does. 
To leverage more local benefit the challenge is to link up 
different externally supported initiatives to expand and 
improve public and non-profit procurement and distri-
bution of medicines, on the one hand, to initiatives for 
more effective local purchasing of medicines by public 
and non-profit procurement bodies, whether national or 
international, on the other hand.
STRENGTHENING LOCAL PROCUREMENT 
AGENCIES AND PROCUREMENT LINKAGES 
WITH LOCAL FIRMS
Local public procurement agencies work in difficult 
environments, often with uncertain and erratic funding 
both locally and externally, and under conflicting pres-
sures. They have also displayed a mixed record in terms 
of probity, efficiency and effectiveness. External agencies 
are working to improve delivery. In that context, support-
ing development of local competence in local purchasing 
offers a route to improvement of response times, as well as 
local industrial benefits. The MEDS example showed that 
working closely with local firms can create more flexible 
and responsive supply, and provide incentives for both 
sides to strengthen quality assurance, communication and 
contracting skills. 
International procurement agencies are, as shown above, 
working on ways to engage with local suppliers. These 
more open procurement practices by externally funded 
programmes are welcomed by local manufacturers and 
promise a more diverse and sustainable supplier base for 
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medicines procurement for local health systems. The level 
of flexibility given by external funders to procurement 
agents varies, however, with different levels of openness to 
working with local producers. More consistent support by 
funders for external agencies’ local purchasing initiatives 
promises substantial local benefits by making local health 
system supply chains more robust over time.  
STRENGTHENING REGULATORY 
PERFORMANCE AND HARMONISATION
Closely allied to procurement support is the need to sup-
port and strengthen the capability of national regulatory 
agencies, help them to sustain their skills, experienced 
staff and political autonomy, and to improve their equip-
ment, procedures, enforcement and decision-making 
powers. African initiatives to build national regulatory 
skills and to strengthen national regulatory authorities 
have received substantial external support, and, as argued 
above, regulation is the key to quality improvement in the 
health sector and within manufacturers. 
In 2017 interviews, one of the most appreciated forms of 
external support was at the regional EAC level for moves 
towards regulatory harmonisation, including shared 
guidelines, improved information systems, and moves 
towards shared inspections and product registration and 
approvals36. Market integration providing easier access 
by local manufacturers to regional markets is a route to 
lower-cost and more efficient local supply. From the health 
sector point of view, the payoff to improved regional regu-
latory performance is more availability of assured quality 
local products. Experienced and skilled local regulators 
can ensure incentives and pressures for upgrading to 
GMP standards while avoiding industrial collapse. Local 
interviewees identified policy silos that can be usefully 
integrated to improve regulatory performance, e.g. in Ken-
ya, linking joint inspections and product approvals to the 
GMP roadmap. External actors can play a role in identify-
ing problems and conflicts among related initiatives, and 
finding scope for compromise and synergy.  
STRENGTHENING TECHNOLOGICAL 
UPGRADING AND QUALITY ASSURANCE
Regulatory requirements for market entry are the single 
most important incentive to raise standards. However, 
local firms struggle to achieve the major improvements re-
quired to meet GMP standards and WHO prequalification. 
Key challenges include investment funding for new plants 
and equipment. Local African initiatives to tackle this in-
clude work by the AUC and NEPAD with the Federation of 
African Pharmaceutical Manufacturers Associations in a 
Technical Working Committee to set up a Fund for Africa’s 
Pharmaceutical Development (FAPD)37. External agencies 
can support initiatives such as FAPD to provide long-term 
capital for the industry to develop and produce quality 
assured medicines.  
However, firms interviewed in Tanzania and Kenya did not 
see finance as the most important hurdle. Infrastructural 
support, including land, water and power connections, 
was strongly appreciated. But firms’ central concerns were 
technological and organisational. Technical assistance, 
such as that provided by German and Japanese develop-
ment cooperation, and also by WHO, is a key resource to 
allow firms to meet quality standards. A number of the 
most successful local manufacturers are joint ventures 
incorporating technology transfer, and external actors can 
play a role in bringing local firms together with potential 
commercial partners. In the EAC, German development 
cooperation is working with UNIDO and the German 
metrology institute PTB to support infrastructure for 
improving quality, including laboratory upgrading, and 
supporting the improvement of National Standards Bu-
reaux. They have been helping to set up chemical refer-
ence standards, improving post-market surveillance, and 
supporting proficiency testing in laboratories. This type of 
quality-focused support for upgrading contributes strong-
ly to both industrial and health agendas. 
SUPPORTING SUSTAINED IMPROVEMENTS 
IN SCIENTIFIC, TECHNOLOGICAL AND 
INNOVATION CAPABILITIES
Technological upgrading is not a one-off, but a continuous 
process. To underpin and sustain an improving industrial 
sector and support innovations in health care, African 
countries need to grow and sustain scientific, clinical 
and innovation capabilities in universities, government, 
regulatory agencies and industrial firms. External support 
can help to achieve this, in particular by working with 
local initiatives, directly or through public-private partner-
ships. The example of Biovac, above, is one indicator of the 
pockets of scientific and technological excellence on the 
continent that can be effectively supported by external as-
sistance. Interviews in Kenya in 2015, as well as discussions 
with vaccine manufacturers in 2016 and 2017, all highlight-
ed innovative, forward-looking international procurement 
and assured market access as key catalysts for continuous 
investment in innovative capabilities by local firms.
36  http://documents.worldbank.org/curated/en/578521468261309041/text/PID-Appraisal-Print-P155163-01-11-2016-1452524510362.txt 
    and interviews 2017
37   www.au.int/web/sites/default/files/newsevents/workingdocuments/32187-wd-rev_of_sa19094_e_original_position_paper_on_establ_of_fap-d-clean.pdf  ,  
       accessed 11 June 2017
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SUPPORTING AND ENCOURAGING MAJOR 
IMPROVEMENTS IN SKILLS AND TRAINING
Skills and training in pharmaceutical fields were argued 
above to be a core, yet still neglected need for both health 
and industry: many relevant policy documents fail to 
address the pharmaceutical skills gap that constrains 
both health system and industrial performance. Expert 
pharmaceutical commentators and representatives of pro-
fessional bodies emphasised that skills were a long-term 
investment that was being neglected across the health and 
industrial sectors. The government, one interviewee em-
phasised, should be defining the skills needed and provid-
ing scholarships now to send people abroad to train in the 
higher-level specialisms. There is frustration that health 
and industrial investment strategies are missing the key 
element of investment in people. Missing skills that could 
be developed with external support include procurement 
and pharmaceutical management skills in the health 
sector, given the severe shortage of expert pharmaceuti-
cal staff in health facilities and logistical roles to support 
better medicines access. 
External support is also needed for the whole range of 
industrial pharmacy and related skills, including man-
agement and GMP-related production control capabilities 
for quality assurance, and formulation and laboratory 
qualifications. Where investments have been made, they 
need be fully exploited by tailoring training to industrial 
and regulatory needs. For example, investment by German 
development cooperation in a well-equipped industrial 
pharmacy training unit at St Luke’s School of Pharmacy in 
Moshi has supported the training of regulatory staff from 
the region. However, industrial firms have argued for bet-
ter adaptation of programmes to the staffing constraints 
they face. There is also a need for equipment maintenance 
training. External investors in training can work with 
local health and industrial interests to ensure their initia-
tives are designed to play a full role in skills development, 
including curriculum improvement and training that 
addresses the health-industrial interface.  
Other training needs where external actors can bridge 
health and industrial needs include formulation and 
development (F&D) skills in local firms to extend product 
range, which requires hands-on work with industrially 
experienced teachers. One interviewee commented that 
there are Indian companies who would help, as collabo-
rators to teach by example. External support for formal 
partnerships of this type would be very valuable and help 
local industry to innovate and adapt for local needs.
ENGAGING WITH NATIONAL POLICIES TO 
COMBINE INDUSTRIAL PROTECTION WITH 
COMPETITION AND LOW PRICES 
Governments in East Africa, certainly in Tanzania, Kenya, 
Uganda and Ethiopia, are looking at the ‘Ghana model’ of 
consistent and sustained government support and protec-
tion for the local pharmaceutical industry (see above). Key 
criticisms of industrial protection focus on the impact on 
prices and hence access, and external bodies are playing an 
important role in observing and documenting price differ-
ences (Ewen et al 2017). The challenge to external funders 
and other external actors, such as NGOs and the WHO, is 
to move away from principled opposition to all forms of 
industrial protection for pharmaceuticals, characterising 
tariffs as a tax on illness (Olcay and Laing 2005), towards a 
more nuanced and evidence-based position accepting the 
need for well-designed and time-limited protection (West 
and Banda 2016). The policy challenge is to ensure that, in 
the context of some ‘infant industry’ protection to allow 
firms to grow, domestic market competition is maintained 
and enhanced. External actors can contribute experience 
of effective competition legislation, undertake collabora-
tive research that investigates price trends and their deter-
minants, and support regional integration to enlarge local 
firms’ scope for operation at scale. These are examples of 
constructive and critical engagement with a local policy 
agenda looking towards medium-term development of 
both industry and health. 
CONVENING AND PROBLEM-SOLVING: 
WORKING TOWARDS COHERENCE
One of the most appreciated roles of external agencies 
such as Germany’s implementing organisations GIZ and 
PTB, in the interviews with industrialists, can be de-
scribed as their convening power. GIZ support has been 
important in establishing the Federation of East African 
Pharmaceutical Manufacturers (FEAPM), the regional 
manufacturers’ association, and in supporting manufac-
turers in improving their access to political levels. There is 
a perception that advocacy and working across ministries 
over perhaps 10 years, across the region, has led to more 
effective cross-sectoral public-private and health-industry 
consultation and policy debate, underlining the impor-
tance of sustaining good intersectoral working relation-
ships as policies develop. 
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One experienced interviewee commented that a few key 
policy documents are essential to get industry-health 
collaboration started. However, he added, it is possible to 
waste a lot of time trying to ensure high-level coherence 
between policy documents in the early stages. Several 
interviewees pushed instead for an early focus on imple-
mentation, in the form of action plans, implementation 
processes, getting particular projects to work, and de-
veloping and using key legislative instruments. Where 
regional agreements lag, bilateral agreements between 
countries on particular issues – such as one East African 
country buying ARVs from another – can move the re-
gional integration agenda forward step by step. 
At national level, a Ministry of Health interviewee made 
the same point sharply: the aim was to promote more 
high-quality local production, one project at a time, 
solving issues and problems for each project through 
collaborative activity across ministries. The issue might 
be land for a new investor, or shifting local procurement 
practices within the existing legislative framework. It 
might be finding a way for a country, within the EAC zero 
external tariff, to institute some other forms of industrial 
protection for nascent industries. The industrial econo-
mist John Sutton has described38 similarly the approach of 
the Ethiopian investment authority, working in detail on 
solving practical problems and constraints, investment by 
investment. 
These arguments and approaches resonate with a strand in 
the current international policy literature (Srinivas 2016) 
that argues for a ‘problem-solving’ approach to develop-
ment planning – an approach that builds up government 
capability by addressing specific problems in detail, in a 
collaborative way, rather than too much focus on policy 
documents. The Ministry of Health official quoted above 
said of this, their current way of working, ‘we used to 
think very narrowly’, but not anymore. 
The proposition from these reflections is that external 
support can operate in assisting specific projects and 
issues, yet still achieve broader goals. There were some 
criticisms in the interviews of external actors who focused 
rather too much on running workshops. Interviewees’ 
appreciation was much greater for specific, agreed and 
targeted support for particular locally identified initia-
tives and linkage-building. A continuing policy debate, 
shaped by a few key policy documents and legislative 
instruments, can then galvanise more key stakeholders to 
join in, strengthening the benefits and improving policy 
coherence over time. Policy coherence is important, but it 
may be best thought of as an outcome of shared working 
on specific tasks, rather than a precondition or input to 
health-industry joint working. 
38  John Sutton, keynote talk at the REPOA Annual Research Workshop, Dar es Salaam, 2017. 
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Conclusion: industrial 
development as a social 
determinant of health 
There are many ways in which industrial development 
influences health, from employment and working con-
ditions to levels of income and tax generated, as well as 
linkages with other allied sectors. This Evidence Brief 
has concentrated on a narrower set of effects: it has used 
stakeholder interviews and reviews of scholarly and prac-
tice literature to analyse the ways in which developmental 
synergies can be extracted from local pharmaceutical 
industrial development, associated technological and 
skills upgrading, and procurement of good quality local 
products for local access and use in health care.  
This process of building health-industry synergy can be 
kick-started by top-level national or regional political 
leadership, as has been occurring in Tanzania, Kenya, 
Uganda and the EAC.  A virtuous circle of support for in-
dustrial investment linked to improved local procurement 
procedures and funding and increased access by low-in-
come patients can be achieved, but it requires substantial 
policy, infrastructure and funding commitment. The last 
section has suggested that a national project-based and 
problem-solving policy approach, with external support, 
can greatly contribute to success: it can create visible 
associations between improved business profits, expand-
ing employment and strengthened health care, generat-
ing new patterns of collaboration and improved policy 
coherence. 
To support these processes, development agencies and 
funders may need to enlarge their vision of the boundaries 
of their role and the tenor of their strategic focus, and at 
the same time shift patterns of involvement further. Inter-
national health agencies, even when working on both sides 
of the health-industry ‘fence’ do not easily link up these 
spatial and temporal activities. An example is The Global 
Fund, whose active though limited contribution to health 
system strengthening appears at present to be delinked 
from its efforts to promote local procurement. Similarly, 
the WHO’s role in supporting technical upgrading by 
manufacturers, while linked to achieving WHO-prequali-
fication, is not linked into its health system strengthening 
work in any clearly articulated way. 
As discussed above, public health has enlarged its vision 
recently to include many intersectoral social determinants 
of population health. However, the impact of industrial 
development on health is still generally overlooked. Build-
ing more robust African health systems requires – and 
will effectively employ – the scientific and technological 
capabilities and skills generated by industrial development 
in pharmaceuticals and medical supplies. As African gov-
ernments develop their commitment to industrialisation, 
the global health community has a lot to contribute in 
supporting local health systems to extract the maximum 
benefits for public health. 
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